Facebook
Twitter
LinkedIn

Media Center

FAST/Fellows/CARB-X Round-Up April 2018
Facebook
Twitter
LinkedIn

FAST & Fellows Round-Up

    • Inflammatix (FAST Fall 2017) is named a finalist in Fast Company’s 2018 World Changing Ideas Awards for its novel HostDx™ tests Read More
    • Fatma Kaplan, CEO of Pheronym (FAST Fall 2017) talks about encountering high risk to get to the goal in sight Read More
    • LogicInk (FAST Spring 2017) highlighted in the Proceedings of the National Academy of Sciences (PNAS): “Science and Culture: Wearable tech meets tattoo art in a bid to revolutionize both” Read More
    • Eidos Therapeutics (FAST Spring 2016) announced completion of a $64.0 million Series B financing to advance Eidos’ small molecule product candidate, AG10 into Phase 2 clinical trials for the treatment of transthyretin (TTR) amyloidosis (ATTR) Read More
    • Sandstone Diagnostics (FAST Fall 2013) deployed in a new NIH-funded research study to further evaluate the association between men’s semen parameters and fertility among couples trying to conceive Read More

CARB-X Updates

    • Read Kevin Outterson, Executive Director of CARB-X‘s op-ed in Stat News on innovative ways to pay for new antibiotics Read More
    • CARB-X awards up to $2 million to HelixBind for the development of the company’s RaPID/BSI diagnostic test for invasive bloodstream infections Read More
    • CARB-X awards up to $7.6 million to Shionogi to develop an antibiotic to treat infections caused by carbapenem-resistant Enterobacteriaceae (CRE) Read More
    • CARB-X awards up to $1.7 million to Specific Diagnostics to support the development of a rapid accurate test to diagnose life-threatening drug-resistant infections in the blood Read More
    • Powered by CARB-X company, Macrolide Therapeutics announced completion of a $20 million financing led by Advent Life Sciences, Gurnet Point Capital, Novartis Venture Fund, Roche Ventures and SR One and appointment of a new CEO Read More
    • Powered by CARB-X company, T2 Biosystems, announced positive results from four studies of its T2Dx blood diagnostics system designed to detect pathogens that cause sepsis Read More